Recent insights on the medicinal chemistry of sickle cell disease

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Sickle Cell Disease (SCD) is a prevalent global genetic hematological disorder.
• It stems from a specific mutation in the beta-globin chain of hemoglobin, causing red blood cell sickling under deoxygenation.
• Current treatment relies on hydroxyurea, an antineoplastic drug.

Purpose of the Study:

• To review current knowledge on potential therapeutic targets for Sickle Cell Disease.
• To explore novel compound discovery approaches for SCD symptom management.
• To discuss drug design strategies, including molecular modifications.

Main Methods:

• Literature review of existing research on SCD.
• Analysis of therapeutic targets and drug discovery methodologies.
• Discussion of drug design principles for SCD treatment.

Main Results:

• Identified various potential molecular targets for SCD intervention.
• Outlined strategies for discovering and designing new therapeutic compounds.
• Highlighted the importance of molecular modification in drug development.

Conclusions:

• There is a need for novel therapeutic strategies beyond hydroxyurea for SCD.
• Drug design and target identification are crucial for advancing SCD treatment.
• Further research into molecular modifications can yield effective SCD therapies.